Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix, Inc. (SNGX) reported results of its September 17, 2026 annual meeting, where stockholders approved an amendment to its Certificate of Incorporation increasing authorized common stock from 75,000,000 to 125,000,000, effective upon filing with the Delaware Secretary of State on September 17, 2026.
Stockholders also approved a charter amendment authorizing the board, for up to one year, to implement a reverse stock split of issued and outstanding common stock at a ratio between 1-for-2 and 1-for-20, with the exact ratio to be set and publicly announced by the board. All five director nominees were elected, say-on-pay and an annual frequency for future say-on-pay votes were approved, the appointment of Cherry Bekaert LLP as auditor for 2026 was ratified, and an adjournment proposal was approved.
Separately, Soligenix disclosed that on June 26, 2026 it filed a prospectus supplement increasing by $2,500,000 the maximum aggregate amount of common stock issuable under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC. The company has previously sold approximately $6,234,000 of common stock under prior supplements covering up to $6,406,000.
SOLIGENIX, INC. (SNGX) reported that director Jerome B. Zeldis received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share, expire on June 16, 2036, and vest in four equal installments from December 17, 2026 through September 17, 2027. No Rule 10b5-1 trading plan is reported for this grant.
SOLIGENIX, INC. (SNGX) reported that director Robert J. Rubin received a grant of 78,947 stock options on September 17, 2026. The options have an exercise price of $0.38 per share, expire on September 16, 2036, and vest ratably on four dates through September 17, 2027.
SOLIGENIX, INC. (SNGX) reported that director Diane L. Parks received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share, expire on September 16, 2036, and vest ratably on four dates through September 17, 2027.
SOLIGENIX, INC. (SNGX) reported that director Anthony Gregg Lapointe received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share and expire on September 16, 2036.
The option grant vests ratably on December 17, 2026, March 17, 2027, June 17, 2027, and September 17, 2027. All 78,947 option shares are held directly following this grant, and no Rule 10b5-1 trading plan is reported.
Soligenix, Inc. filed a prospectus supplement covering the offer and sale by the company of 5,330,560 shares of common stock underlying previously issued common warrants, and incorporated its Quarterly Report for the period ended June 30, 2026. The company operates two segments, Specialized BioTherapeutics and Public Health Solutions, and remains a development-stage biopharmaceutical business with no grant or product revenue in the quarter.
For the three months ended June 30, 2026, Soligenix reported a net loss of $1.99 million (basic and diluted loss per share $0.12), versus $2.70 million in the prior-year quarter. For the first six months of 2026, net loss was $4.81 million versus $5.65 million a year earlier. Cash and cash equivalents were $9.81 million at June 30, 2026, up from $7.94 million at December 31, 2025, aided by $6.04 million of gross proceeds from at-the-market equity sales under the Rodman Sales Agreement.
Management reports working capital of $6.50 million and believes existing cash can fund operations into the second quarter of 2028, yet nonetheless states that substantial doubt exists about the company’s ability to continue as a going concern, as strategic alternatives and additional program assets have not been secured. In April 2026 an interim analysis led to a recommendation to halt the FLASH2 Phase 3 trial of HyBryte for cutaneous T-cell lymphoma for futility, and the Board terminated the HyBryte development program in June 2026. On June 10, 2026, Soligenix received a Nasdaq notice for non-compliance with the $1.00 minimum bid price requirement and has until December 7, 2026 to regain compliance, with the possibility of an additional 180-day extension or a delisting process thereafter.
Soligenix, Inc. filed a prospectus supplement covering 408,640 shares of common stock issuable upon exercise of previously issued common warrants and incorporated its Quarterly Report for the period ended June 30, 2026. The company reported no revenue and a six‑month net loss of $4,812,319, driven by $2,756,391 in research and development and $2,227,910 in general and administrative expenses.
Cash and cash equivalents were $9,811,141, with working capital of $6,499,947. Management projects cash runway into the second quarter of 2028 but still concluded there is substantial doubt about its ability to continue as a going concern. The Board terminated the HyBryte™ CTCL program after a Phase 3 trial was halted for futility. Soligenix is funding operations partly through a Rodman at‑the‑market facility, having sold about $6.234 million of stock by June 30, 2026, and faces a Nasdaq minimum bid price deficiency with a compliance deadline of December 7, 2026.
Soligenix, Inc. is registering 4,253 shares of common stock underlying previously issued common warrants under a shelf prospectus, while also presenting its Quarterly Report for the period ended June 30, 2026.
For Q2 2026, the company reported no revenue and a net loss of $1,987,354, with a six‑month net loss of $4,812,319. Cash and cash equivalents were $9,811,141, and total assets $10,499,470. Shareholders’ equity was $6,645,557 with an accumulated deficit of $249,863,451. Shares outstanding increased to 21,765,479 as of July 31, 2026, driven largely by at‑the‑market (ATM) equity sales.
Management states it has cash runway into the second quarter of 2028, yet also concludes that substantial doubt exists about the company’s ability to continue as a going concern without additional strategic transactions or financing. The lead HyBryte™ program for cutaneous T‑cell lymphoma was terminated in June 2026 after a Phase 3 trial was recommended to halt for futility. In June 2026, Soligenix received a Nasdaq bid‑price deficiency notice, with until December 7, 2026 to regain compliance, potentially via actions such as a reverse stock split.
Soligenix, Inc. filed a prospectus supplement covering the resale of up to 1,054,688 shares of common stock issuable upon exercise of previously issued warrants by selling stockholders. The supplement incorporates the company’s Form 10‑Q for the quarter ended June 30, 2026.
As of June 30, 2026, Soligenix reported cash and cash equivalents of $9.8 million, total assets of $10.5 million, and shareholders’ equity of $6.6 million. The company generated no revenue and recorded a net loss of $1.99 million for the quarter and $4.81 million for the first half of 2026, with an accumulated deficit of $249.9 million. Working capital was $6.5 million, and management projects cash runway into the second quarter of 2028, yet still concluded there is substantial doubt about its ability to continue as a going concern.
Soligenix expanded its Rodman at-the-market facility, selling approximately $6.23 million of common stock through June 30, 2026 and retaining about $2.4 million of remaining capacity as of July 31, 2026. Shares outstanding increased to 21.6 million at June 30, 2026 and 21.8 million at July 31, 2026. In June 2026, the Board terminated the HyBryte™ CTCL development program after a Phase 3 trial was halted for futility, and the related FDA orphan grant study was wound down. The company also disclosed a Nasdaq bid-price deficiency notice received in June 2026, with until December 7, 2026 to regain compliance.
Soligenix, Inc. is a development-stage biopharmaceutical company with two segments and no revenue in the three or six months ended June 30, 2026. Operating expenses declined year over year, with research and development at $2.76 million and general and administrative at $2.23 million for the first half of 2026, leading to a six‑month net loss of $4.81 million versus $5.65 million in 2025.
Cash and cash equivalents were $9.81 million and working capital $6.50 million at June 30, 2026. Management expects existing cash to support operations into the second quarter of 2028, yet explicitly concludes that substantial doubt exists about the company’s ability to continue as a going concern, given ongoing losses and uncommitted funding beyond its at‑the‑market equity program.
During the first half, Soligenix raised $6.04 million via its Rodman at‑the‑market facility, increasing common shares outstanding to 21.64 million. After an interim futility analysis in April 2026, the Board terminated development of its lead HyBryte™ CTCL program in June 2026. The company also disclosed a Nasdaq notice for failure to meet the $1.00 minimum bid price, with an initial compliance period through December 7 2026.